Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.47 |
| ▸ | MPO | P05164 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.47 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.46 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.46 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.46 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.46 |
| ▸ | DHODH | Q02127 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
| ▸ | FABP3 | P05413 | 1/20 | 0.45 |
| ▸ | FABP4 | P15090 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12483334 | 0.85 | LMNA (0.51) | MAPTKDM4ENPC1RAB9AMAPK14 | |
| SCHEMBL12482709 | 0.84 | POLB (0.54) | MAPTKDM4EPOLBTDP1NPC1 | |
| SCHEMBL28741354 | 0.83 | MPO (0.56) | MAPTKDM4EPOLBMAPK14MPO | |
| SCHEMBL13285184 | 0.78 | MPO (0.54) | MAPTPOLBMAPK14MPOCLCN2 | |
| SCHEMBL786240 | 0.78 | ALDH1A1 (0.63) | MAPTKDM4EPOLBTDP1NPC1 | |
| SCHEMBL12941890 | 0.76 | DHODH (0.50) | MAPTNPC1RAB9AMPOALDH1A1 | |
| SCHEMBL4863266 | 0.76 | MAP2K1 (0.51) | MAPTMAPK14ALDH1A1GAACLCN2 | |
| SCHEMBL5753034 | 0.76 | MAPK14 (0.58) | MAPTMAPK14ALDH1A1GAASOS1 | |
| SCHEMBL27510760 | 0.75 | MAPK13 (0.72) | MAPTPOLBNPC1RAB9AMAPK14 | |
| SCHEMBL12482895 | 0.75 | P2RX7 (0.58) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140073651-A1 | BENZAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140073651-A1 | BENZAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | P2RX3, P2RX7, P2RX1 | MAPT 4210/4885KDM4E 2905/4885POLB 4438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.